Byondis Announces First Patient Dosed in Phase 1 Clinical Trial of Novel SIRPα-Directed Monoclonal Antibody BYON4228 in Patients With Advanced or Metastatic Solid Tumors
NIJMEGEN, The Netherlands:
Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces the first patient dosed in its Phase 1 dose escalation and expansion BYON4228.002 clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of novel SIRPα-directed monoclonal antibody (mAb) BYON4228 alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors.
Advertisement
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603807653/en/
Louis Denis, MD, Chief Medical Officer, Byondis
BYON4228 is a potential best-in-class novel mAb that targets and blocks the CD47-SIRPα axis, responsible for tumors' ability to escape from recognition and destruction by the immune system. By targeting SIRPα and not CD47, BYON4228 offers selective targeting of myeloid cells and avoids disruption of other biologically meaningful CD47-dependent interactions. In preclinical studies, BYON4228 was found to potentiate the tumor killing capacity of tumor-targeting mAbs tested without the toxicity associated with CD47 agents.
'Building on strong preclinical data, we believe that there is broad potential for BYON4228 alone and in combination with tumor-targeting mAbs, checkpoint inhibitors and antibody drug conjugates and other modalities across hematological and solid tumors,' said Louis Denis, MD, Chief Medical Officer, Byondis. 'We look forward to evaluating the results of this trial to support the clinical development of BYON4228 alone and in combination with other agents and to bring a new therapeutic option to patients with high unmet medical need.'
Part 1 of the BYON4228.002 trial will evaluate the safety of BYON4228 alone and in combination to determine the maximum tolerated dose (MTD), or optimal biological dose (OBD) if the MTD is not reached, and recommended combination dose regimen(s) for expansion (RDE(s)). The second part of the trial will evaluate the objective tumor response rate (ORR). The secondary objectives of this trial are safety, pharmacokinetics, immunogenicity and preliminary efficacy. The trial will be conducted at multiple sites across Europe, including the United Kingdom, Belgium and Spain.
About BYON4228
BYON4228 is a novel monoclonal antibody (mAb) from Byondis' next generation immuno-oncology (IO) program that targets and blocks the CD47-SIRPα axis, responsible for tumors' ability to escape from recognition and destruction by the immune system. BYON4228 is currently being studied in two Phase 1 Clinical Trials evaluating BYON4228 alone and in combination with Rituximab in patients with Relapsed/Refractory CD20 positive B-cell Non-Hodgkin's Lymphoma (NHL) (NCT05737628) and BYON4228 alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors (NCT06932952).
About Byondis
Driven to improve patients' lives, Byondis is an independent clinical stage fully integrated biopharmaceutical research and development company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) with a focus on antibody-drug conjugates and antibody-based therapeutics.
Byondis' broad development portfolio comprises preclinical and early-stage clinical programs. The product candidates combine Byondis' expertise in linker-drug (LD) technology, antibody-drug conjugation, targeted cytotoxic therapy, immunology, and monoclonal antibody (mAb) development. Byondis' expertise covers all preclinical R&D from early lead finding to production of clinical batches of the selected product candidates, which are all done in-house.
The company's headquarters and state-of-the-art R&D and GMP manufacturing facilities are based in Nijmegen, the Netherlands. For more information visit www.byondis.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250603807653/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
DocuSign: Questions Around Growth Remain
DocuSign posted revenue and earnings growth, beating estimates. The company's free cash flow fell slightly, and its full-year forecast underwhelmed investors. DocuSign has steadied itself, but investors are not yet seeing clear answers to the question of how growth can accelerate from here. 10 stocks we like better than Docusign › Here's our initial take on DocuSign's (NASDAQ: DOCU) financial report. Metric Q1 FY25 Q1 FY26 Change vs. Expectations Revenue $709.6 million $763.7 million 8% Beat Earnings per share (adjusted) $0.82 $0.90 10% Beat Non-GAAP billings $709.5 million $739.6 million 4% n/a Free cash flow $232.1 million $227.8 million -2% n/a There was a lot to like about DocuSign's latest quarter. Revenue and adjusted earnings per share were up 8% and 10%, respectively, topping Wall Street expectations. GAAP (generally accepted accounting principles) gross margin came in at 79.4%, up 5 basis points from a year ago, and the company posted solid free cash flow of $227.8 million. DocuSign also surpassed the 10,000 Intelligent Agreement Management customer threshold during the period. Billings rose 4% in the quarter, but DocuSign warned that it expects momentum to fade as the year goes on. For fiscal 2026, DocuSign is now forecasting total billings of $3.285 billion and $3.39 billion, down from its prior guidance for $3.3 billion to $3.4 billion. The billings revision, though slight, highlights the biggest challenge facing DocuSign right now. The business is healthy and profitable, but investors are worried about where growth will come from. The company is forecasting full-year fiscal 2026 revenue of $3.15 billion to $3.16 billion, which, at the midpoint, would represent just a 5% gain from last year's $2.98 billion in total revenue. DocuSign is putting its cash to work for investors, announcing a new $1 billion repurchase program. But with the company's share count up nearly 6% in just the last three years, much of the buyback would only serve to offset share-based compensation that has added to the float. Investors were more focused on the look ahead than the results. DocuSign shares were down 15% in aftermarket trading following the release but ahead of the company's call with investors. CEO Allan Thygesen, who has been on the job since October 2022, called the results "an important quarter for Docusign's long-term transformation," highlighting the company's "ambitious product roadmap." Expect investors to press Thygesen for specifics about how the transformation is going and when it will translate into real, sustained growth. DocuSign invented its category and continues to hold strong in its core business, even up against competition from Adobe (NASDAQ: ADBE) and Microsoft (NASDAQ: MSFT), which can incorporate e-signatures into broader offerings. But Wall Street is forward-looking. Shares of DocuSign are up nearly 75% over the past year as an initial response to Thygesen's turnaround ambitions. Until investors gain confidence that DocuSign has found a formula to expand its core offering and generate significant revenue growth, the stock could face limits on its ability to accelerate higher from here. Full earnings report Investor relations page Before you buy stock in Docusign, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Docusign wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor's total average return is 997% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Lou Whiteman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Adobe, Docusign, and Microsoft. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. DocuSign: Questions Around Growth Remain was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
Trump looks to close 105-year-old department that supports women workers despite insinuating it would stay
The Department of Labor said it would 'eliminate' the Women's Bureau, a century-old department that focuses on advocating for economic equality and safe working environments for women, despite the secretary insinuating it was here to stay. When pressed with questions about the Department of Government Efficiency cutting grants administered by the Women's Bureau at a House Appropriations Committee meeting on May 15, Secretary Lori Chavez-DeRemer responded by emphasizing its history. 'Statutorily, the Women's Bureau is in statute,' Chavez-DeRemer said in response to Representative Rosa DeLauro's concerns. While Chavez-DeRemer's comment stopped short of a promise, she did not elaborate on the future of Women's Bureau, but insinuated the 105-year-old department was here to stay. Yet the Department of Labor's 2026 fiscal year budget in brief anticipates eliminating the Women's Bureau, calling it a 'relic of the past' and 'an ineffective policy.' 'The Department will work with Congress to craft a repeal package of WB's organic statutes, including the Women in Apprenticeship in Non-Traditional Occupations grant authorization. Apprenticeship work will be handled by the Employment and Training Administration,' the Bureau of Labor wrote. The Independent has asked the Department of Labor and the White House for comment. The elimination of the bureau, by giving it no funding in 2026, is the latest move by the Trump administration to override Congress's authority and get rid of previously appropriated funds for what it believes is unnecessary or does not align with the president's policies. During his presidential campaign, Trump promised to be women's 'protector' and insisted they would be 'happy, healthy, confident and free' under his administration. However, the Trump administration believes the Women's Bureau 'has struggled to find a role' in advancing the interests of women in the workforce, according to the budget brief. 'The Bureau works on a wide range of issues and its work is not always closely coordinated with, or informed by, the agencies that actually have the resources to address the issues at hand,' the Department wrote in its FY 2026 budget in brief. Established by Congress in 1920, the Women's Bureau is the only federal agency mandated to represent the needs of wage-earning women. It conducts research and policy analysis to advocate for policies that improve working conditions and increase profitable opportunities for women in the workforce. That includes getting more women to high-paying jobs, expanding access to paid leave and affordable child care, eliminating pay inequality, as well as harassment in the workplace. Part of its role includes grant-making and managing the Women in Apprenticeship and Nontraditional Occupations grant program. The Women's Bureau also has the authority to investigate and report on matters about the welfare of women in industry to the Department of Labor. Nine current or former Department of Labor staffers told Mother Jones they believe shuttering the Women's Bureau aligns with the administration's desire to have women stop working and stay home to raise children. 'It really feels like a specific [effort] to get women out of the workplace,' Gayle Goldin, the former deputy director of the Women's Bureau under the Biden administration, told Mother Jones. 'We really still need the Women's Bureau, because we need to be able to identify what the problems are, see where the barriers are for women in the workplace, and ensure that women have full capacity to enter the workplace in whatever job they want.'
Yahoo
3 hours ago
- Yahoo
Mid-cap stocks offer 'a place to play' amid trade uncertainty
Markets (^GSPC, ^IXIC, ^DJI) remain near recent highs as investors wait on trade deal details ahead of the July truce deadline. Robinhood Markets chief investment officer, Stephanie Guild, joins Morning Brief to discuss how diversification and sector positioning could help investors navigate the uncertainty. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. We're still within 200 points of the S&P 500 high at this juncture with no deals right now. I mean okay, US UK uh if if we want to count that. But at the end of the day for all of the talk that we're seeing emerge from both sides and whether that is the US and China, whether that's the US and India. We're still waiting for the details of these deals to really figure out how investors can also trade on that. So what should investors be using as their checklist as we do see some of the details come out around these deals if we do see them prior to the end of this truce period, which is up in just about a month here. July 9th. Yeah the first one anyway. Um I think there's I think there's a couple of things. One is that whenever I hear like I think a good barometer has actually been listening to Treasury percent, Treasurer percent. I think he's like when he went out on Face the Nation on Sunday like some of the things he said has already started like he talked about how the deficit is not going to be as big issue and that the CBO was not taking into account, you know, some of the the tariff revenue. And then, you know, I think it was yesterday they said actually we're going to cut the deficit by 400 billion over the next 10 years. I mean, who knows what will happen over the next 10 years, but at least the plan is not to raise it. And that is good for interest rates, right? And interest rates do drive valuation. So I think that's he to me has been a good barometer because what he does say comes true. And I do think there's going to, I personally think there's going to be deals. So the way we started managing money we have a stra uh product called Robin Hood strategies and in it we've actually been um pretty diversified where we have allocations to some international equities because that's why I think like you have to have some of that diversification not just thinking about the US in this global environment because if there are deals, then those non-US investments are going to probably do well, and then you'll have some cyclical growth names do well here as well. Can we double click on the cyclical growth names and why do you think that that is potentially a better investment than the likes of continuing to double down on an Nvidia for example? I'm not saying don't do things like Nvidia, but I think markets have gotten pretty well valued, right? Like I think you know even with earnings estimates coming down, valuations are fair at best if you look out to 2026, right? They're around 20 times. In the mid-cap space for example though, you've actually seen valuations come down because you've seen earnings estimates come down, but you've actually seen like prices come down even more and they haven't rallied back. And so that's why I say like in the mid-cap space is a maybe a place to play. Um and then you end up getting you know kind of a mix of things that um of pro-cyclical things, right? And then things that are maybe a little more defensive versus I I'm still not a fan of small caps for example because it's just still too focused on there. But I also think like financials is a a place to consider um because I do think what everyone's forgotten about in the midst of tariffs is that there is this other side of the administration's policy, which is like M&A and deregulation and financials is probably a place that will benefit from that. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
